Quick Hits
– Following up on his Letter to the Editor in the New York Times, Alex Waldrop presses his response to Joe Drape’s drugs-in-racing commentary of last week with a Blood-Horse column and a short blog post, both of which amp up the defensiveness of the original reaction to little effect, other than to make the NTRA and the Safety Alliance appear as irrelevant as critics charge and to expose the limits of industry self-regulation. (It doesn’t help that Waldrop outlandishly claims in the Blood-Horse, “Race-day medications have been virtually eliminated nationwide,” when Lasix remains legal everywhere and phenylbutazone is widely used in California and elsewhere.) That’s unfortunate, especially as racing heads into a season of increased scrutiny.
– Yesterday’s news: David Lanzman sells 50% of I Want Revenge to IEAH. Today’s news: IEAH sells 25% of Stardom Bound to David Lanzman. Foolish Pleasure questions if the deal — which, according to one report, was for $2 million + the share in Stardom Bound + bonuses — is a sign that IEAH is struggling to muster capital. I wondered if Joe Talamo would really retain the mount on the Gotham winner, as the press release announcing the deal stated. Asked during the Tuesday NTRA teleconference about just that point, Lanzman vehemently replied, “It’s Joe’s horse … I can’t imagine taking the kid off.” Note to Talamo: Don’t screw up in the Wood.
– The first HANA sponsored buy-cott was a success, with total handle on the selected race up nearly 100%. Well done, horseplayers.
3 Comments